BPMC Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -43.9% compared to Blueprint Medicines's net margin of 8.48%. Blueprint Medicines's return on equity of -50.13% beat Eli Lilly and's return on equity of 66.4%.

Blueprint Medicines has a consensus price target of $125.00, signalling upside risk potential of 20.94%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.39%. Given that Eli Lilly and has higher upside potential than Blueprint Medicines, analysts believe Eli Lilly and is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Blueprint Medicines pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Blueprint Medicines's net income of -$56.3M is lower than Eli Lilly and's net income of $970.3M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 86.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.93x versus 17.65x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -43.9% compared to Blueprint Medicines's net margin of -54.2%. Blueprint Medicines's return on equity of -50.13% beat PTC Therapeutics's return on equity of --.

Blueprint Medicines has a consensus price target of $125.00, signalling upside risk potential of 20.94%. On the other hand PTC Therapeutics has an analysts' consensus of $58.36 which suggests that it could grow by 32.48%. Given that PTC Therapeutics has higher upside potential than Blueprint Medicines, analysts believe PTC Therapeutics is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $128.2M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Blueprint Medicines's net income of -$56.3M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.93x versus 3.74x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -43.9% compared to Blueprint Medicines's net margin of 36.03%. Blueprint Medicines's return on equity of -50.13% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Blueprint Medicines has a consensus price target of $125.00, signalling upside risk potential of 20.94%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,029.20 which suggests that it could grow by 44.61%. Given that Regeneron Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Regeneron Pharmaceuticals is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Blueprint Medicines's net income of -$56.3M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.93x versus 5.96x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -43.9% compared to Blueprint Medicines's net margin of 37.71%. Blueprint Medicines's return on equity of -50.13% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Blueprint Medicines has a consensus price target of $125.00, signalling upside risk potential of 20.94%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $489.81 which suggests that it could grow by 18.49%. Given that Blueprint Medicines has higher upside potential than Vertex Pharmaceuticals, analysts believe Blueprint Medicines is more attractive than Vertex Pharmaceuticals.

Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Blueprint Medicines's net income of -$56.3M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.93x versus 10.12x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.